DBV Technologies

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, DBV Technologies sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials 1 currently recruiting 9 completed top decile by trial count

DBV Technologies: 11 sponsored US clinical trials, 1 recruiting.

DBV Technologies sponsors 11 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 9 completed. 6 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Peanut Allergy, with 2 trials.

Top-decile sponsor footprint

DBV Technologies ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

11 total, page 1 of 1

RECRUITING Phase 3

Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)

NCT07003919
ACTIVE NOT RECRUITING Phase 3

Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age

NCT05741476
COMPLETED Phase 3

Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

NCT03859700
COMPLETED Phase 1

A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects

NCT03352726
COMPLETED Phase 3

Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age

NCT03211247
COMPLETED Phase 3

Safety Study of Viaskin Peanut to Treat Peanut Allergy

NCT02916446
COMPLETED Phase 3

Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy

NCT02636699
COMPLETED Phase 1

Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy

NCT02223182
COMPLETED Phase 2

Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children

NCT01955109
COMPLETED Phase 2

Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy

NCT01675882
COMPLETED Phase 1

Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy

NCT01170286

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 2
Phase 3 6

Therapeutic Areas

Peanut Allergy 2
Allergy, Peanut 1
Allergy 1

What is open in the DBV Technologies pipeline

1 recruiting of 11 indexed (9% open); 9 completed (82%).

Phase mix: 6 late (III/IV) vs 5 early (I/II) (balanced across stages).

Top condition: Peanut Allergy (2 trials), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

DBV Technologies: open-pipeline peers nationwide

Peers matched on 11 registered trials and 9% open enrollment, not the therapeutic-area sidebar.

DBV Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 020406080 0%2%4%6%8%10% Total trials Recruiting share DBV TechnologiesAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiomeAlkermesFlorida Gulf Coast UniversityGenfitHiberCell
DBV Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

DBV Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 trials (± recruiting share)

Sponsors near 9% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this DBV Technologies page

11 registered trials is a research-attention snapshot, not an endorsement of DBV Technologies or any single study.

  • 1 of DBV Technologies's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Peanut Allergy is the condition DBV Technologies studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Peanut Allergy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

DBV Technologies pipeline card: 11 registered trials from official public datasets.Report a data error.